Global Respiratory Partnering 2010-2017: Deal trends, players and financials

Description:

Global Respiratory Partnering 2010 to 2017 provides the full collection of Respiratory disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Respiratory partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Respiratory partnering agreement structure
Respiratory partnering contract documents
Top Respiratory deals by value
Most active Respiratory dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Respiratory disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Respiratory deals.

The report presents financial deal terms values for Respiratory deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Respiratory dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Respiratory dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Respiratory deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Respiratory dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Respiratory deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Respiratory partnering deals by specific Respiratory target announced since 2010. The chapter is organized by specific Respiratory therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Respiratory partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Respiratory partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Respiratory technologies and products.

Report scope:

Global Respiratory Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Respiratory trends and structure of deals entered into by leading companies worldwide.

Global Respiratory Partnering 2010 to 2017 includes:

- Trends in Respiratory dealmaking in the biopharma industry since 2010
- Analysis of Respiratory deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Respiratory deal contract documents
- Comprehensive access to over 3500 Respiratory deal records
- The leading Respiratory deals by value since 2010
- Most active Respiratory dealmakers since 2010

The report includes deals for the following indications: Allergic rhinitis, Acute respiratory distress syndrome, Asthma, Bronchitis, Chronic obstructive pulmonary disease, Emphysema, Idiopathic pulmonary fibrosis, Occupational Lung Disease, Asbestosis, Coalworkers pneumoconiosis, Hypersensitivity pneumonitis, Silicosis, Pneumonia, Pulmonary arterial hypertension, Pulmonary embolism, Respiratory Tract Infection, Sarcoidosis, Sinusitis, Breathlessness, Bronchospasm, Chest Pain, Cough, Nasal congestion, Snoring, Wheeze, plus other respiratory indications.

In Global Respiratory Partnering 2010 to 2017, available deals and contracts are listed by:

- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Respiratory Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 400 respiratory deals. Analyzing actual contract agreements allows assessment of the following:

- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Contents:

Executive Summary

1. Introduction

2. Trends in Respiratory dealmaking
   2.1. Introduction
   2.2. Respiratory partnering over the years
   2.3. Respiratory partnering by deal type
   2.4. Respiratory partnering by industry sector
   2.5. Respiratory partnering by stage of development
   2.6. Respiratory partnering by technology type
   2.7. Respiratory partnering by therapeutic indication

Chapter 3 -Financial deal terms for Respiratory partnering

3.1. Introduction
3.2. Disclosed financials terms for Respiratory partnering
3.3. Respiratory partnering headline values
3.4. Respiratory deal upfront payments
3.5. Respiratory deal milestone payments
3.6. Respiratory royalty rates

4. Leading Respiratory deals and dealmakers
   4.1. Introduction
   4.2. Most active in Respiratory partnering
   4.3. List of most active dealmakers in Respiratory
   4.4. Top Respiratory deals by value

5. Respiratory contract document directory
   5.1. Introduction
5.2. Respiratory partnering deals where contract document available

6. Respiratory dealmaking by therapeutic target
   6.1. Introduction
   6.2. Deals by Respiratory therapeutic target

Appendices

Appendix 1 - Directory of Respiratory deals by company A-Z 2010 to 2017
Appendix 2 - Directory of Respiratory deals by deal type 2010 to 2017
Appendix 3 - Directory of Respiratory deals by stage of development 2010 to 2017
Appendix 4 - Directory of Respiratory deals by technology type 2010 to 2017

Further reading on dealmaking
Deal type definitions

About

CurrentPartnering

Table of figures

Figure 1: Respiratory partnering since 2010
Figure 2: Respiratory partnering by deal type since 2010
Figure 3: Respiratory partnering by industry sector since 2010
Figure 4: Respiratory partnering by stage of development since 2010
Figure 5: Respiratory partnering by technology type since 2010
Figure 6: Respiratory partnering by indication since 2010
Figure 7: Respiratory deals with a headline value
Figure 8: Respiratory deals with upfront payment values
Figure 9: Respiratory deals with milestone payment
Figure 10: Respiratory deals with royalty rates
Figure 11: Active Respiratory dealmaking activity- 2010 to 2017
Figure 12: Top Respiratory deals by value since 2010
Ordering:

Order Online - http://www.researchandmarkets.com/reports/2229065/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Respiratory Partnering 2010-2017: Deal trends, players and financials
Web Address: http://www.researchandmarkets.com/reports/2229065/
Office Code: SC2GLVQT

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) Single User</td>
<td></td>
<td>USD 2995</td>
</tr>
<tr>
<td>Electronic (PDF) 1 - 5 Users</td>
<td></td>
<td>USD 4495</td>
</tr>
<tr>
<td>Electronic (PDF) Site License</td>
<td></td>
<td>USD 8995</td>
</tr>
<tr>
<td>Electronic (PDF) Enterprisewide</td>
<td></td>
<td>USD 14995</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr, [ ] Mrs, [ ] Dr, [ ] Miss, [ ] Ms, [ ] Prof
First Name: ___________________________________________ Last Name: ________________________________
Email Address: * _______________________________________
Job Title: ______________________________________________
Organisation: __________________________________________
Address: ______________________________________________
City: __________________________________________________
Postal / Zip Code: _____________________________________
Country: ______________________________________________
Phone Number: __________________________________________
Fax Number: ___________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World